Alnylam, Medtronic Release Preclinical Data from Huntington's Disease Program

The newly released preclinical data shows that direct delivery of huntingtin-targeted siRNAs induced "robust silencing" of the huntingtin mRNA, with the effect observed at "substantial distances from the infusion site," the companies said.